A comprehensive review of finerenone—a third-generation non-steroidal mineralocorticoid receptor antagonist [PDF]
Frontiers in Cardiovascular MedicineMultiple studies have shown that finerenone (BAY 94-8862), a third-generation non-steroidal mineralocorticoid receptor antagonist (MRA), possesses different or superior mechanisms of action to traditional MRAs.
Shuhui Zhai +3 more
doaj +4 more sources
Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Improves Diastolic Dysfunction in Preclinical Nondiabetic Chronic Kidney Disease [PDF]
Journal of the American Heart Association: Cardiovascular and Cerebrovascular DiseaseBackground The mineralocorticoid receptor plays a significant role in the development of chronic kidney disease (CKD) and associated cardiovascular complications.
Ixchel Lima Posada +9 more
doaj +4 more sources
Use of nonsteroidal mineralocorticoid receptor antagonist in chronic kidney disease: A case report of a patient with Fabry disease in his mid-20s [PDF]
Journal of International Medical ResearchFabry disease is a rare X-linked lysosomal storage disorder caused by a defect in glycosphingolipid metabolism, which leads to the accumulation of globotriaosylceramide (Gb3) in various cell types.
Guan-Qiang Tian +5 more
doaj +2 more sources
The Pharmacokinetics of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone. [PDF]
Clin Pharmacokinet, 2023 Finerenone, a selective and nonsteroidal antagonist of the mineralocorticoid receptor, has received regulatory approval with the indication of cardiorenal protection in patients with chronic kidney disease associated with type 2 diabetes. It is rapidly and completely absorbed and undergoes first-pass metabolism in the gut wall and liver resulting in a ...
Heinig R, Eissing T.
europepmc +3 more sources
Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease [PDF]
Frontiers in Pharmacology, 2021 Diabetic kidney disease (DKD) is a major cause of end-stage kidney disease (ESKD) worldwide. Mineralocorticoid receptor (MR) plays an important role in the development of DKD.
Daiji Kawanami +6 more
doaj +3 more sources
Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease [PDF]
Endocrinology and Metabolism, 2023 Chronic kidney disease (CKD) is the most common cause of end-stage renal disease in patients with type 2 diabetes mellitus (T2DM). CKD increases the risk of cardiovascular diseases; therefore, its prevention and treatment are important. The prevention of
Dong-Lim Kim, Seung-Eun Lee, Nan Hee Kim
doaj +2 more sources
Structural Mechanism of a Partial Glucocorticoid Receptor Agonist Functioning as a Mineralocorticoid Receptor Antagonist [PDF]
Structural DynamicsThe Glucocorticoid Receptor (GR) and Mineralocorticoid Receptor (MR) are homologous ligand-activated transcription factors that regulate extensive downstream gene expression networks involved in metabolism, development, electrolyte homeostasis, and ...
Xu Liu
doaj +2 more sources
Nonsteroidal Mineralocorticoid Receptor Antagonist (Finerenone) in Cardiorenal Disease [PDF]
Journal of Clinical Medicine, 2023 Emaad Abdel-Rahman +2 more
exaly +2 more sources
Finerenone as a Nonsteroidal Mineralocorticoid Receptor Antagonist for Lupus Nephritis [PDF]
Kidney International ReportsMingfang Sun +4 more
doaj +2 more sources
Mineralocorticoid Receptor Antagonists [PDF]
International Cardiovascular Forum Journal, 2019 Two mineralocorticoid receptor antagonists, spironolactone and eplerenone, are currently approved by the FDA. Several non-steroid based ligands are in clinical trials for indications including heart failure, hypertension and diabetic kidney disease, and even more structurally distinct chemical series are reported in the literature with preclinical data
Anneli, Nordqvist, Kenneth L, Granberg
+5 more sources